Harrow (HROW) Income from Non-Controlling Interests (2019 - 2020)
Harrow (HROW) recorded quarterly Income from Non-Controlling Interests of -$8000.0 in Q4 2020, up 46.67% quarter-over-quarter from -$15000.0 in Q3 2020, and up 87.69% on a YoY basis from -$4262.3 in Q1 2020.
Harrow (HROW) Income from Non-Controlling Interests (2019 - 2020) Analysis & Trends
Harrow's Income from Non-Controlling Interests history runs 2 years deep, the most recent figure standing at -$8000.0 for Q4 2020.
- In Q4 2020, Income from Non-Controlling Interests rose 87.69% year-over-year to -$8000.0; the TTM figure through Dec 2020 stood at -$62000.0 (up 61.01% YoY), while the FY2020 annual figure was -$62000.0, up 78.84% from the prior year.
- Income from Non-Controlling Interests was -$8000.0 for Q4 2020 at Harrow, up from -$15000.0 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $42000.0 in Q2 2019 to a low of -$161000.0 in Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | - |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | - |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 22.56 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | - |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | - |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | - |
| 10 | Harrow | 1.25 Bn | 1.15 Bn | 27.05 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | -8,000.00 |
| Sep 30, 2020 | -15,000.00 |
| Jun 30, 2020 | -23,000.00 |
| Mar 31, 2020 | -16,000.00 |
| Dec 31, 2019 | -65,000.00 |
| Sep 30, 2019 | -161,000.00 |
| Jun 30, 2019 | 42,000.00 |
| Mar 31, 2019 | 25,000.00 |